SlideShare uma empresa Scribd logo
1 de 8
Finerenone
Kerendia®
周孫鴻藥師
開發背景
 第二型糖尿病,若血糖沒控制好容易產
生小血管病變~腎臟、視網膜和周邊神
經病變
 若第二型糖尿病且有嚴重蛋白尿(例如
UACR≥300 mg/day),能服用ACEI或ARB
來減緩腎功能惡化; 但血壓太低或血鉀
太高不適合用
 若第二型糖尿病且蛋白尿,能服用
SGLT2i來減緩腎功能惡化和心血管事
件; 但eGFR <30 mL/min/1.73 m2 或有截
肢風險的人不適合用
機轉
 Finerenone 透過抑制礦物性皮質
激素受體 (mineralocorticoid
receptor),能增加血中鉀離子,也能
減少心臟、腎臟和血管的發炎及
纖維化
好處
 若第二型糖尿病且蛋白尿,
finerenone能減緩腎功能惡化和
心血管事件
劑量
腎功能 劑量
eGFR ≥60 mL/minute/1.73
m2
每天一次,20mg
eGFR ≥25 to <60
mL/minute/1.73 m2
每天一次,10mg
eGFR <25 mL/minute/1.73
m2
不建議使用
上述劑量還要考量血中鉀離子,太高要減量甚至不要用
副作用
 高血鉀
 低血壓
 低血鈉
交互作用
 Finerenone本身經由肝臟酵素
CYP3A4代謝
 所以若併用到CYP3A4抑制劑或
CYP3A4促進劑,要調整劑量

Mais conteúdo relacionado

Mais procurados

Sodium glucose cotransporter 2 (sglt2) inhibitors
Sodium glucose cotransporter 2 (sglt2) inhibitorsSodium glucose cotransporter 2 (sglt2) inhibitors
Sodium glucose cotransporter 2 (sglt2) inhibitorsMoh'd sharshir
 
Diabetes Remission and Prevention
Diabetes Remission and PreventionDiabetes Remission and Prevention
Diabetes Remission and PreventionUsama Ragab
 
Dpp4i earlier the better ! (1)
Dpp4i  earlier the better ! (1)Dpp4i  earlier the better ! (1)
Dpp4i earlier the better ! (1)Faraz Farishta
 
T2DM Therapeutic Area Landscape: SGLT2 and GLP1 (USA Market)
T2DM Therapeutic Area Landscape: SGLT2 and GLP1 (USA Market)T2DM Therapeutic Area Landscape: SGLT2 and GLP1 (USA Market)
T2DM Therapeutic Area Landscape: SGLT2 and GLP1 (USA Market)Sarfraz Khan
 
Diabetic Kidney Disease
Diabetic Kidney DiseaseDiabetic Kidney Disease
Diabetic Kidney Diseasedrsanjaymaitra
 
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials ...
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials  ...Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials  ...
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials ...magdy elmasry
 
Early Initiation of Insulin:Basal bolus versus premixed insulin-Dr Shahjada S...
Early Initiation of Insulin:Basal bolus versus premixed insulin-Dr Shahjada S...Early Initiation of Insulin:Basal bolus versus premixed insulin-Dr Shahjada S...
Early Initiation of Insulin:Basal bolus versus premixed insulin-Dr Shahjada S...Bangabandhu Sheikh Mujib Medical University
 
Insulin therapy in type 2 diabetes
Insulin therapy in type 2 diabetesInsulin therapy in type 2 diabetes
Insulin therapy in type 2 diabetesMohsen Eledrisi
 
Insulin degludec n Insulin peglispro
Insulin degludec n Insulin peglisproInsulin degludec n Insulin peglispro
Insulin degludec n Insulin peglisproArsalan Masoud
 
Management of dm in ckd
Management of dm in ckdManagement of dm in ckd
Management of dm in ckdPraveen Nagula
 
Dapagliflozin in Clinical Trial212.pptx
Dapagliflozin in Clinical Trial212.pptxDapagliflozin in Clinical Trial212.pptx
Dapagliflozin in Clinical Trial212.pptxAliShahen2
 
Hypoglycemia & Management of Diabetes in CKD Stage V
Hypoglycemia & Management of Diabetes in CKD Stage VHypoglycemia & Management of Diabetes in CKD Stage V
Hypoglycemia & Management of Diabetes in CKD Stage VMa Wady
 
Empagliflozin and Cardiovascular Outcomes
Empagliflozin and Cardiovascular OutcomesEmpagliflozin and Cardiovascular Outcomes
Empagliflozin and Cardiovascular OutcomesUyen Nguyen
 
Insulin therapy: art of initiation and titration
Insulin therapy: art of initiation and titration Insulin therapy: art of initiation and titration
Insulin therapy: art of initiation and titration Saikumar Dunga
 

Mais procurados (20)

Sodium glucose cotransporter 2 (sglt2) inhibitors
Sodium glucose cotransporter 2 (sglt2) inhibitorsSodium glucose cotransporter 2 (sglt2) inhibitors
Sodium glucose cotransporter 2 (sglt2) inhibitors
 
Diabetes Remission and Prevention
Diabetes Remission and PreventionDiabetes Remission and Prevention
Diabetes Remission and Prevention
 
Dpp4i earlier the better ! (1)
Dpp4i  earlier the better ! (1)Dpp4i  earlier the better ! (1)
Dpp4i earlier the better ! (1)
 
T2DM Therapeutic Area Landscape: SGLT2 and GLP1 (USA Market)
T2DM Therapeutic Area Landscape: SGLT2 and GLP1 (USA Market)T2DM Therapeutic Area Landscape: SGLT2 and GLP1 (USA Market)
T2DM Therapeutic Area Landscape: SGLT2 and GLP1 (USA Market)
 
Diabetic Kidney Disease
Diabetic Kidney DiseaseDiabetic Kidney Disease
Diabetic Kidney Disease
 
UKPDS overview
UKPDS overviewUKPDS overview
UKPDS overview
 
Empagliflozin glycemic control and beyond-Dr Shahjada Selim
Empagliflozin glycemic control and beyond-Dr Shahjada SelimEmpagliflozin glycemic control and beyond-Dr Shahjada Selim
Empagliflozin glycemic control and beyond-Dr Shahjada Selim
 
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials ...
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials  ...Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials  ...
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials ...
 
Exploring the Science and Practice of GLP-1 Receptor Agonists: An Update on C...
Exploring the Science and Practice of GLP-1 Receptor Agonists: An Update on C...Exploring the Science and Practice of GLP-1 Receptor Agonists: An Update on C...
Exploring the Science and Practice of GLP-1 Receptor Agonists: An Update on C...
 
Early Initiation of Insulin:Basal bolus versus premixed insulin-Dr Shahjada S...
Early Initiation of Insulin:Basal bolus versus premixed insulin-Dr Shahjada S...Early Initiation of Insulin:Basal bolus versus premixed insulin-Dr Shahjada S...
Early Initiation of Insulin:Basal bolus versus premixed insulin-Dr Shahjada S...
 
Dapagliflozin
Dapagliflozin Dapagliflozin
Dapagliflozin
 
Insulin therapy in type 2 diabetes
Insulin therapy in type 2 diabetesInsulin therapy in type 2 diabetes
Insulin therapy in type 2 diabetes
 
Insulin degludec n Insulin peglispro
Insulin degludec n Insulin peglisproInsulin degludec n Insulin peglispro
Insulin degludec n Insulin peglispro
 
CARVEDILOL MORE THAN MERE A BETA-BLOCKER
CARVEDILOL MORE THAN MERE A BETA-BLOCKERCARVEDILOL MORE THAN MERE A BETA-BLOCKER
CARVEDILOL MORE THAN MERE A BETA-BLOCKER
 
Management of dm in ckd
Management of dm in ckdManagement of dm in ckd
Management of dm in ckd
 
Dapagliflozin in Clinical Trial212.pptx
Dapagliflozin in Clinical Trial212.pptxDapagliflozin in Clinical Trial212.pptx
Dapagliflozin in Clinical Trial212.pptx
 
Dapagliflozin- a novel SGLT2 inhibitor
Dapagliflozin- a novel SGLT2 inhibitorDapagliflozin- a novel SGLT2 inhibitor
Dapagliflozin- a novel SGLT2 inhibitor
 
Hypoglycemia & Management of Diabetes in CKD Stage V
Hypoglycemia & Management of Diabetes in CKD Stage VHypoglycemia & Management of Diabetes in CKD Stage V
Hypoglycemia & Management of Diabetes in CKD Stage V
 
Empagliflozin and Cardiovascular Outcomes
Empagliflozin and Cardiovascular OutcomesEmpagliflozin and Cardiovascular Outcomes
Empagliflozin and Cardiovascular Outcomes
 
Insulin therapy: art of initiation and titration
Insulin therapy: art of initiation and titration Insulin therapy: art of initiation and titration
Insulin therapy: art of initiation and titration
 

Mais de 孫鴻 周

預防化療引起的 噁心與嘔吐
預防化療引起的噁心與嘔吐預防化療引起的噁心與嘔吐
預防化療引起的 噁心與嘔吐孫鴻 周
 
三高用藥評估3
三高用藥評估3三高用藥評估3
三高用藥評估3孫鴻 周
 
三高用藥案例2
三高用藥案例2三高用藥案例2
三高用藥案例2孫鴻 周
 
三陰性乳癌 標靶新藥Sacituzumab
三陰性乳癌標靶新藥Sacituzumab三陰性乳癌標靶新藥Sacituzumab
三陰性乳癌 標靶新藥Sacituzumab孫鴻 周
 
三高用藥評估案例1
三高用藥評估案例1三高用藥評估案例1
三高用藥評估案例1孫鴻 周
 
藥物引起的暈厥
藥物引起的暈厥藥物引起的暈厥
藥物引起的暈厥孫鴻 周
 
接骨木莓果是做什麼用?
接骨木莓果是做什麼用?接骨木莓果是做什麼用?
接骨木莓果是做什麼用?孫鴻 周
 
肺炎鏈球菌 十五價疫苗
肺炎鏈球菌十五價疫苗肺炎鏈球菌十五價疫苗
肺炎鏈球菌 十五價疫苗孫鴻 周
 
心衰竭需注意藥物
心衰竭需注意藥物心衰竭需注意藥物
心衰竭需注意藥物孫鴻 周
 
紫錐菊對 COVID19有效嗎?
紫錐菊對COVID19有效嗎?紫錐菊對COVID19有效嗎?
紫錐菊對 COVID19有效嗎?孫鴻 周
 
NSCLC的 免疫療法
NSCLC的免疫療法NSCLC的免疫療法
NSCLC的 免疫療法孫鴻 周
 
CLA 共軛亞麻油酸
CLA 共軛亞麻油酸CLA 共軛亞麻油酸
CLA 共軛亞麻油酸孫鴻 周
 
NSCLC化療比較
NSCLC化療比較NSCLC化療比較
NSCLC化療比較孫鴻 周
 
(老人用藥)Clonidine
(老人用藥)Clonidine(老人用藥)Clonidine
(老人用藥)Clonidine孫鴻 周
 
Cinnamon肉桂
Cinnamon肉桂Cinnamon肉桂
Cinnamon肉桂孫鴻 周
 
非小細胞肺癌的化療選擇
非小細胞肺癌的化療選擇非小細胞肺癌的化療選擇
非小細胞肺癌的化療選擇孫鴻 周
 
抗生素新藥Cefiderocol
抗生素新藥Cefiderocol抗生素新藥Cefiderocol
抗生素新藥Cefiderocol孫鴻 周
 
(老人用藥)甲型阻斷劑
(老人用藥)甲型阻斷劑(老人用藥)甲型阻斷劑
(老人用藥)甲型阻斷劑孫鴻 周
 
藻類保健食品
藻類保健食品藻類保健食品
藻類保健食品孫鴻 周
 

Mais de 孫鴻 周 (20)

預防化療引起的 噁心與嘔吐
預防化療引起的噁心與嘔吐預防化療引起的噁心與嘔吐
預防化療引起的 噁心與嘔吐
 
三高用藥評估3
三高用藥評估3三高用藥評估3
三高用藥評估3
 
三高用藥案例2
三高用藥案例2三高用藥案例2
三高用藥案例2
 
三陰性乳癌 標靶新藥Sacituzumab
三陰性乳癌標靶新藥Sacituzumab三陰性乳癌標靶新藥Sacituzumab
三陰性乳癌 標靶新藥Sacituzumab
 
三高用藥評估案例1
三高用藥評估案例1三高用藥評估案例1
三高用藥評估案例1
 
藥物引起的暈厥
藥物引起的暈厥藥物引起的暈厥
藥物引起的暈厥
 
接骨木莓果是做什麼用?
接骨木莓果是做什麼用?接骨木莓果是做什麼用?
接骨木莓果是做什麼用?
 
肺炎鏈球菌 十五價疫苗
肺炎鏈球菌十五價疫苗肺炎鏈球菌十五價疫苗
肺炎鏈球菌 十五價疫苗
 
心衰竭需注意藥物
心衰竭需注意藥物心衰竭需注意藥物
心衰竭需注意藥物
 
紫錐菊對 COVID19有效嗎?
紫錐菊對COVID19有效嗎?紫錐菊對COVID19有效嗎?
紫錐菊對 COVID19有效嗎?
 
NSCLC的 免疫療法
NSCLC的免疫療法NSCLC的免疫療法
NSCLC的 免疫療法
 
CLA 共軛亞麻油酸
CLA 共軛亞麻油酸CLA 共軛亞麻油酸
CLA 共軛亞麻油酸
 
NSCLC化療比較
NSCLC化療比較NSCLC化療比較
NSCLC化療比較
 
(老人用藥)Clonidine
(老人用藥)Clonidine(老人用藥)Clonidine
(老人用藥)Clonidine
 
Cinnamon肉桂
Cinnamon肉桂Cinnamon肉桂
Cinnamon肉桂
 
非小細胞肺癌的化療選擇
非小細胞肺癌的化療選擇非小細胞肺癌的化療選擇
非小細胞肺癌的化療選擇
 
抗生素新藥Cefiderocol
抗生素新藥Cefiderocol抗生素新藥Cefiderocol
抗生素新藥Cefiderocol
 
(老人用藥)甲型阻斷劑
(老人用藥)甲型阻斷劑(老人用藥)甲型阻斷劑
(老人用藥)甲型阻斷劑
 
藻類保健食品
藻類保健食品藻類保健食品
藻類保健食品
 
肺癌概論
肺癌概論肺癌概論
肺癌概論
 

新藥介紹Finerenone